Colorado to Limit GLP-1 Coverage for State Employees, Saving $17 Million Annually
核心洞察
Colorado plans to restrict insurance coverage of GLP-1 (搜索) medications like Wegovy and Ozempic for its 40,000 state employees, limiting access to only those with Type 2 diabetes (搜索), cardiovascular disease (搜索), or sleep apnea.
The policy change, effective July 1, aims to save nearly $17 million annually as the state faces a $750 million budget shortfall, with GLP-1 (搜索) prescription costs having increased from $1.5 million to $7 million in just 18 months.
Critics, including state lawmakers who use these medications, argue the decision could reverse health improvements and ultimately increase healthcare costs by allowing preventable conditions to develop.
In a significant cost-cutting measure, Colorado officials have announced plans to restrict insurance coverage of popular weight-loss medications for approximately 40,000 state employees. Beginning July 1, the state will only cover Glucagon-like peptide-1 (GLP-1 (搜索)) medications such as Wegovy and Ozempic for employees with specific medical conditions, potentially affecting thousands of current users.
The Colorado Department of Personnel & Administration (DPA) will continue covering GLP-1 (搜索) medications for employees diagnosed with Type 2 diabetes (搜索), cardiovascular disease (搜索) with history, and obstructive sleep apnea (搜索). However, those using these medications solely for weight management will need to pay out-of-pocket, with costs exceeding $1,000 monthly.
Rapidly Escalating Costs Drive Decision
State officials cite exponential growth in prescription costs as the primary driver behind the decision. According to DPA data, expenditures for GLP-1 (搜索) medications have increased dramatically:
- July-December 2023: $1.5 million
- January-June 2024: $4 million
- July-December 2024: $7 million
"The number of GLP-1 (搜索) prescriptions covered by the state of Colorado has caused costs to double every six months," explained Doug Platt, a DPA spokesman. "In a difficult budget environment, tough decisions must be made by the legislature to deliver a balanced budget."
The policy change is expected to save Colorado approximately $16.8 million in fiscal year 2025-2026, helping address a projected $750 million state budget shortfall.
Impact on State Employees
The decision could significantly impact thousands of state workers currently using these medications. According to Colorado WINS, the state employees union, approximately:
- 3,422 state employees were prescribed Wegovy in 2024
- 2,000 were taking Ozempic
- 1,100 were using Zepbound (another GLP-1 medication)
DPA reports that 854 state employees have GLP-1 (搜索) prescriptions specifically for obesity (搜索) treatment as of July 2024, with the average state cost per prescription approaching $1,300.
Without insurance coverage, patients face substantial out-of-pocket expenses:
- Wegovy: approximately $1,349 per month
- Ozempic: approximately $969 per month
Medical and Policy Concerns
State Senator Dafna Michaelson Jenet, who uses GLP-1 (搜索) medications to treat obesity (搜索), has vocally opposed the change. "We are going to be thrown back into a health state that is dangerous and expensive to care for," she told the Colorado Sun. "It's just so maddening that we have this medicine that solves a problem and we're saying it's not an important enough problem to solve."
Michaelson Jenet, who was prediabetic before starting GLP-1 (搜索) treatment and has since lost 50 pounds, introduced legislation last year that would have required private health insurance companies and Medicaid to cover these medications. The bill failed in committee after nonpartisan analysts estimated it would cost the state $86 million in the first year and at least $200 million subsequently.
She has introduced similar legislation this year, though prospects appear dim given budget constraints.
Alternative Support and Precedent
The DPA notes it will continue offering wellness programs to support employees seeking weight loss, including nutritional counseling and personal training. Adrian Schulte, communications director at the DPA, emphasized these programs aim to help "participants reach and sustain healthy weight management" through developing "lifelong skills."
Colorado is not the first state to limit GLP-1 (搜索) coverage. West Virginia and North Carolina, both states with high obesity (搜索) rates, previously reversed coverage decisions for state employees due to financial considerations.
Broader Implications
GLP-1 (搜索) medications have gained immense popularity since their approval for diabetes treatment and weight management. According to a May 2024 poll by KFF, 12 percent of U.S. adults had tried weight loss drugs, with 6 percent currently using them.
These medications decrease appetite and slow digestion, helping patients lose weight and control blood sugar levels. However, benefits typically reverse when patients discontinue use.
Hilary Glasgow, executive director of Colorado WINS, criticized the decision as "shortsighted," noting it could have disproportionate impacts on women, who comprise the majority of GLP-1 (搜索) users. "It's shortsighted to eliminate coverage that helps prevent obesity (搜索)-related diseases that are often treated with other expensive drugs," Glasgow stated.
The final decision on the policy change will be made through the legislature's budgeting process, with the Polis administration reportedly agreeing to discuss potential solutions with the state employees union.